Beth Fand Incollingo


Sotorasib Shows Encouraging Antitumor Activity in Advanced NSCLC

September 20th 2020

The investigational drug sotorasib demonstrated promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation, an aberration for which no targeted treatment has yet been approved.

Selinexor Triplet Improves Response, Reduces Neuropathy in Relapsed/Refractory Multiple Myeloma

May 29th 2020

When added to bortezomib and dexamethasone in patients with multiple myeloma, selinexor, an inhibitor of XPO1-mediated nuclear export, improves progression-free survival and overall response rate and reduces the incidence of peripheral neuropathy.

Cancer Mortality Rate Declined More Steeply in States That Expanded Medicaid Under the Affordable Care Act

May 14th 2020

The cancer mortality rate declined more in states that expanded Medicaid coverage than those that didn’t following the passage of the Affordable Care Act of 2010, a study found.

Exercise Helps Women Maintain Cardiovascular Function During Adjuvant Breast Cancer Treatment

December 7th 2018

Women who took part in a supervised exercise program during adjuvant treatment for breast cancer had better cardiovascular function than women who did not participate in the program.

Even Moderate Weight Loss Helps Prevent Breast Cancer in Postmenopausal Women

December 9th 2017

Losing even some extra weight significantly reduces the risk of breast cancer for postmenopausal women, expert says.

Pregnancy Does Not Increase Recurrence Risk of Early-Stage, ER-Positive Breast Cancer

June 3rd 2017

Women who have had early breast cancer, along with their doctors, often worry that pregnancy could cause disease recurrence. But according to the results of a new study, that’s not the case.

Late Effects of Childhood Cancers Dropping Along With Intensity of Treatments

June 3rd 2017

The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.

Adopting Healthy Lifestyle Leads to Improved Overall Survival in Postsurgical Colon Cancer

May 18th 2017

Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.

BRCA Gene Does Not Predict Poor Prognosis in Patients With Breast Cancer

January 10th 2017

While mutations of the BRCA gene can increase a woman’s chances of developing breast and ovarian cancers, the presence of the gene made no difference in survival for women aged 40 years or younger who were diagnosed with early-stage breast cancer.

Adding Temozolomide to Radiotherapy Is Effective and Tolerable in Older Adults With Glioblastoma

June 5th 2016

Adding temozolomide to short-course radiotherapy after surgery boosted overall survival by nearly 2 months, bringing 1-year survival rates up from 22.2% to 37.8% for elderly patients with glioblastoma.

Capecitabine Combo Improves Survival in Resected Pancreatic Cancer

June 4th 2016

The addition of capecitabine to standard adjuvant gemcitabine doubled 5-year overall survival (OS) rates for patients with pancreatic cancer whose tumors were surgically removed.

Moving Time-Consuming Chemotherapy Regimens from Inpatient to Outpatient Settings Improves Quality of Life and Saves Money, Study Shows

April 28th 2016

When chemotherapy involves tricky infusion timing, patients are routinely admitted to hospitals to receive their treatments. But what would happen if these drugs could be administered successfully on an outpatient basis?

Lynne Malestic Named CURE's 2016 Extraordinary Healer During 10th Annual Award Celebration

April 28th 2016

Lots of people take their work home with them, but Lynne Malestic, RN, has given the idea new meaning.

An Upstanding Role: How Nurses Can Help Prevent Patient Falls

April 28th 2016

The possibility that hospitalized cancer patients will fall is an ongoing concern among the medical professionals who care for them.

Newer Agents, Combinations Being Studied for Targeted Therapies in CLL

March 20th 2016

Targeted agents, particularly ibrutinib and idelalisib, are becoming increasingly important in the treatment of chronic lymphocytic leukemia, and have replaced chemotherapy in many settings.

Genomics Help Customize Therapy in Non-Hodgkin Lymphoma

March 19th 2016

With the R-CHOP chemotherapy regimen considered the backbone of therapy for treatment-naïve patients with non-Hodgkin lymphoma, researchers are now delving further into the genome to pave the way for therapeutic improvements.

Ibrutinib Bests Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma

December 7th 2015

Ibrutinib sparks more durable remissions than temsirolimus in patients with relapsed or refractory mantle cell lymphoma.

Frontline Ibrutinib Significantly Improves Survival in CLL

December 6th 2015

Ibrutinib reduced the risk of death by 84% versus chlorambucil in treatment-naïve elderly patients with chronic lymphocytic leukemia.

Ruxolitinib Continues to Impress in Long-Term Myelofibrosis Follow-Up

December 5th 2015

Ruxolitinib continues to demonstrate sustained benefits for patients with myelofribrosis in a 5-year follow-up of the phase III COMFORT-II study.

Survivors of Childhood Cancers Living Longer Due to Improvements in Care and Follow-up

May 31st 2015

Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.